Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 335-344

  Sobol, Paul T ^a   Boudreau, Jeanette E ^b   Stephenson, Kyle ^b   Wan, Yonghong ^b   Lichty, Brian D ^b   Mossman, Karen L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERPESVIRUS VECTOR; KM 100; N 212; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; T CELL DEPLETION; TUMOR GROWTH; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79551614963     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.264     Document Type: Article

References (50)

1. Melroe, GT, DeLuca, NA and Knipe, DM (2004). Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol 78: 8411-8420.
2. Mossman, KL, Saffran, HA and Smiley, JR (2000). Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 74: 2052-2056.
3. Stark, GR, Kerr, IM, Williams, BR, Silverman, RH and Schreiber, RD (1998). How cells respond to interferons. Annu Rev Biochem 67: 227-264.
4. Taniguchi, T, Ogasawara, K, Takaoka, A and Tanaka, N (2001). IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623-655.
5. Tagliaferri, P, Caraglia, M, Budillon, A, Marra, M, Vitale, G, Viscomi, C et al. (2005). New pharmacokinetic and pharmacodynamic tools for interferon?(IFN) treatment of human cancer. Cancer Immunol Immunother 54: 1-10.
6. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
7. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
8. Dunn, GP, Sheehan, KC, Old, LJ and Schreiber, RD (2005). IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 65: 3447-3453.
9. Li, Y, Srivastava, KK and Platanias, LC (2004). Mechanisms of type I interferon signaling in normal and malignant cells. Arch Immunol Ther Exp (Warsz) 52: 156-163.
10. Hummel, JL, Safroneeva, E and Mossman, KL (2005). The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 12: 1101-1110.
11. Toda, M, Rabkin, SD, Kojima, H and Martuza, RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393.
12. Nakamori, M, Fu, X, Rousseau, R, Chen, SY and Zhang, X (2004). Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 9: 658-665.
13. Miller, CG and Fraser, NW (2003). Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 7: 741-747.
14. Li, H, Dutuor, A, Tao, L, Fu, X and Zhang, X (2007). Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13: 316-322. (Pubitemid 46121885)
15. Rosenberg, SA, Yang, JC and Restifo, NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
16. Parmiani, G, Castelli, C, Dalerba, P, Mortarini, R, Rivoltini, L, Marincola, FM et al. (2002). Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94: 805-818.
17. Mills, KH (2004). Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4: 841-855.
18. Kusmartsev, S and Gabrilovich, DI (2002). Immature myeloid cells and cancerassociated immune suppression. Cancer Immunol Immunother 51: 293-298.
19. Frey, AB and Monu, N (2006). Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol 79: 652-662.
20. Mathis, D and Benoist, C (2004). Back to central tolerance. Immunity 20: 509-516.
21. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
22. Vigil, A, Martinez, O, Chua, MA and García-Sastre, A (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16: 1883-1890.
23. Zhang, YQ, Tsai, YC, Monie, A, Wu, TC and Hung, CF (2010). Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 18: 692-699.
24. Bridle, BW, Boudreau, JE, Lichty, BD, Brunellière, J, Stephenson, K, Koshy, S et al. (2009). Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 17: 1814-1821.
25. Varghese, S, Rabkin, SD, Nielsen, GP, MacGarvey, U, Liu, R and Martuza, RL (2007). Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 67: 9371-9379.
26. Currier, MA, Gillespie, RA, Sawtell, NM, Mahller, YY, Stroup, G, Collins, MH et al. (2008). Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 16: 879-885.
27. Bennett, JJ, Delman, KA, Burt, BM, Mariotti, A, Malhotra, S, Zager, J et al. (2002). Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945.
28. Fong, Y, Kim, T, Bhargava, A, Schwartz, L, Brown, K, Brody, L et al. (2009). A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 17: 389-394.
29. Turner, DL, Cauley, LS, Khanna, KM and Lefrançois, L (2007). Persistent antigen presentation after acute vesicular stomatitis virus infection. J Virol 81: 2039-2046.
30. Sobol, PT, Hummel, JL, Rodrigues, RM and Mossman, KL (2009). PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Ther 16: 1077-1087.
31. McFadden, G, Mohamed, MR, Rahman, MM and Bartee, E (2009). Cytokine determinants of viral tropism. Nat Rev Immunol 9: 645-655.
32. Guy, CT, Cardiff, RD and Muller, WJ (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
33. Koziol, JA, Maxwell, DA, Fukushima, M, Colmerauer, ME and Pilch, YH (1981). A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 37: 383-390.
34. Ercolini, AM, Ladle, BH, Manning, EA, Pfannenstiel, LW, Armstrong, TD, Machiels, JP et al. (2005). Recruitment of latent pools of high-avidity CD8 (+) T cells to the antitumor immune response. J Exp Med 201: 1591-1602.
35. Wall, EM, Milne, K, Martin, ML, Watson, PH, Theiss, P and Nelson, BH (2007). Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67: 6442-6450.
36. Mossman, KL and Smiley, JR (1999). Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediateearly genes almost entirely dependent on ICP0. J Virol 73: 9726-9733.
37. Chuang, CM, Monie, A, Wu, A, Pai, SI and Hung, CF (2009). Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clin Cancer Res 15: 4581-4588.
38. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
39. Li, MO, Wan, YY, Sanjabi, S, Robertson, AK and Flavell, RA (2006). Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24: 99-146.
40. Jarnicki, AG, Lysaght, J, Todryk, S and Mills, KH (2006). Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177: 896-904.
41. Grinshtein, N, Ventresca, M, Margl, R, Bernard, D, Yang, TC, Millar, JB et al. (2009). High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Ther 16: 338-350.
42. Appay, V, Jandus, C, Voelter, V, Reynard, S, Coupland, SE, Rimoldi, D et al. (2006). New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177: 1670-1678.
43. Obeid, M, Tesniere, A, Ghiringhelli, F, Fimia, GM, Apetoh, L, Perfettini, JL et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61. (Pubitemid 46067386)
44. Ercolini, AM, Machiels, JP, Chen, YC, Slansky, JE, Giedlen, M, Reilly, RT et al. (2003). Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 170: 4273-4280.
45. Bonneau, RH, Salvucci, LA, Johnson, DC and Tevethia, SS (1993). Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology 195: 62-70.
46. Parkhurst, MR, Fitzgerald, EB, Southwood, S, Sette, A, Rosenberg, SA and Kawakami, Y (1998). Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58: 4895-4901.
47. Cai, WZ and Schaffer, PA (1989). Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J Virol 63: 4579-4589.
48. Guy, CT, Webster, MA, Schaller, M, Parsons, TJ, Cardiff, RD and Muller, WJ (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582.
49. O'Brien, J, Wilson, I, Orton, T and Pognan, F (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421-5426.
50. Brown, CW, Stephenson, KB, Hanson, S, Kucharczyk, M, Duncan, R, Bell, JC et al. (2009). The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83: 552-561.